DOI: 10.1128/AAC.00276-17
Article Information
PubMed
Published By
History
- Received February 8, 2017
- Returned for modification February 25, 2017
- Accepted March 15, 2017
- Published online May 24, 2017.
Copyright & Usage
Copyright © 2017 American Society for Microbiology. All Rights Reserved.
Article Versions
- Accepted Manuscript version (March 20, 2017).
- You are viewing the most recent version of this article.
Author Information
- Lucy Chenga,
- Brian C. Nelsonb,
- Monica Mehtab,
- Nikhil Sevala,
- Sarah Parka,
- Marla J. Giddinsa,
- Qiuhu Shic,
- Susan Whittierd,
- Angela Gomez-Simmondsa and
- Anne-Catrin Uhlemanna
- aDepartment of Medicine, Division of Infectious Diseases, Columbia University Medical Center, New York, New York, USA
- bNewYork-Presbyterian Hospital, New York, New York, USA
- cNew York Medical College, Valhalla, New York, USA
- dDepartment of Pathology and Cell Biology, Clinical Microbiology Laboratory, Columbia University Medical Center, New York, New York, USA
- Address correspondence to Anne-Catrin Uhlemann, au2110{at}columbia.edu.
Citation Cheng L, Nelson BC, Mehta M, Seval N, Park S, Giddins MJ, Shi Q, Whittier S, Gomez-Simmonds A, Uhlemann A-C. 2017. Piperacillin-tazobactam versus other antibacterial agents for treatment of bloodstream infections due to AmpC β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 61:e00276-17. https://doi.org/10.1128/AAC.00276-17.
